PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year. But questions around the target’s safety will call for close attention to the therapeutic window.
The findings, from Stanford University’s Crystal Mackall and University of North Carolina Chapel Hill’s Gianpietro Dotti, respectively, move B7-H3 up the flagpole from the class of new immuno-oncology targets to a potential difference-maker in enabling CAR Ts in new, highly underserved indications.
Mackall, a professor of pediatrics and medicine at Stanford, published a study in Clinical Cancer Research demonstrating B7-H3 is broadly expressed in pediatric cancers, mostly at high levels, and showing CAR T cells targeting B7-H3 can shrink tumors in preclinical models.
Mackall also leads the Cancer Moonshot’s Pediatric Immunotherapy Discovery and Development Network (PI-DDN).
Mackall has co-founded CAR T company Lyell Inc. with CEO Rick Klausner, a serial entrepreneur who previously founded and directed Juno Therapeutics Inc., now a subsidiary of Celgene Corp. Former Juno CEO Hans Bishop is a co-founder and board member of Lyell. Arch Venture Partners’ Bob Nelson is on the board. The company has not disclosed financing.
UNC’s Dotti extended the findings with a Feb. 11 paper in Cancer Cell demonstrating B7-H3